Table 1:
Tau Immunotherapies that entered clinical trials
| Drug | Tau epitope | Antibody subclass | Clinical trials | Trial Status | Company |
|---|---|---|---|---|---|
| Active immunization | |||||
| AADvac-1 | Tau294–305 | N/A | NCT02579252, NCT03174886, NCT04445831 | Phase II | Axon Neuroscience SE |
| ACI-35 | p-Tau396/404 | N/A | NCT04445831 | Phase II | AC Immune SA, Janssen |
| Passive immunization | |||||
| APNmAb005 | Conformational epitope | - | NCT05344989 | Phase I | Aprinoia Therapeutics |
| Bepranemab | Tau235–246 | IgG4 | NCT03464227, NCT03605082, NCT04185415, NCT04658199, NCT04867616 | Phase II | UCB Biopharma, Genentech |
| BIIB076 | Mid-region | IgG1 | NCT03056729 | Discontinued | Biogen, Neurimmune, Eisai |
| E2814 | HVPGG motif, Tau299–303 and 362–366 | IgG1 | NCT04231513, NCT04971733, NCT05269394, NCT01760005 | Phase II/III | Eisai |
| Gosuranemab | Tau8–19 | IgG4 |
NCT02460094, NCT02658916, NCT03068468, NCT03658135, NCT03352557 |
Discontinued | Biogen, Bristol- Meyers Squibb |
| JNJ-63733657 | p-Tau217 | - |
NCT03375697 NCT03689153, NCT05407818, NCT04619420 |
Phase I | Janssen |
| Lu AF87908 | p-Tau396 | IgG1 | NCT04149860 | Phase I | H. Lundbeck A/S |
| MK-2214 | Unspecified, possibly p-Tau413 | - | jRCT2031220627, NCT05466422 |
Phase I | Merck |
| PNT001 | Cis p-Tau231 | - |
NCT04096287, NCT04677829 |
Phase I | Pinteon Therapeutics |
| PRX005 | Epitope in R1, R2 and R3 microtubule-binding repeats | - | Not registered | Phase I | Prothena |
| RG7345 | p-Tau422 | - | NCT02281786 | Discontinued | Roche |
| Semorinemab | N-terminus of all six isoforms | IgG4 |
NCT03289143, NCT03828747 |
Phase II | AC Immune SA, Genentech |
| Tilavonemab | Tau25–30 | IgG4 |
NCT02494024, NCT03413319, NCT03391765, NCT03744546, NCT02880956, NCT03712787 |
Discontinued | Abbvie, C2N Diagnostics LLC |
| Zagotenemab | Conformational epitope, Tau7–9 and 312–342 | - |
NCT02754830, NCT03019536, NCT03518073 |
Discontinued | Eli Lilly |